So to clarify this and to make sure I get what you're saying:The kevetrin equivalent dose to mice is about 3 times. P21 showed in mouse studies at 50mg. And based on data from our human trials, we saw early signs of p21 at 50-75mg in humans. Which is pretty amazing that we were told that signs of p21 were seen that early. We should all be excited about how far we are along in the trial and what we can expect going forward.
What level of P21/P53 activation is needed/desired? Why /how was 10% selected as the threshold?
"P21 increased in 6 out of 14 patients"
Actual wording of slide:
P21 increased > 10% in 6 out of 14 patients at relatively low doses of Kevetrin
Last year the wording was:
Kevetrin activated p21 in 4 of 5 patients ...
So, my view is that K may have activated p21 in more than the 6 of 14 as shown on the slide, but some were below the 10% threshold. Perhaps it was 11 of 12 that showed "activation".
This particular slide (2014, slide #4) also has the DF & BI logo at the bottom. I believe that CTIX cleared this slide and all K related content of this presentation with DF & BI and they approved this.
What level of P21/P53 activation is needed/desired? Why /how was 10% selected as the threshold?